"The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach./"...
Persons taking Cesamet (nabilone capsules) should be alerted to the potential for additive central nervous system depression resulting from simultaneous use of Cesamet (nabilone capsules) and alcohol or other central nervous system depressants such as benzodiazepines and barbiturates. This combination should be avoided. Patients receiving treatment with Cesamet (nabilone capsules) should be specifically warned not to drive, operate machinery, or engage in any hazardous activity. Patients using Cesamet (nabilone capsules) should be made aware of possible changes in mood and other adverse behavioral effects of the drug so as to avoid panic in the event of such manifestations. Patients should remain under supervision of a responsible adult while using Cesamet (nabilone capsules) .
Last reviewed on RxList: 2/26/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Cesamet Information
Cesamet - User Reviews
Cesamet User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.